News & Events about Seagen Inc.
Seagen Inc. (Nasdaq: SGEN) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 after the close of U.S. financial markets. Following the announcement, Company management will host a conference call and webcast at 4:30 p.m...
Seagen Inc. (NASDAQ:SGEN Get Rating) CMO Roger D. Dansey sold 7,500 shares of the companys stock in a transaction dated Thursday, January 5th. The shares were sold at an average price of $135.00, for a total transaction of $1,012,500.00. Following the completion of the sale, the chief...
Seagen Inc. (Nasdaq:SGEN) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 3:00 p.m. Pacific Time. The presentation will be webcast live and available for replay from the investor section of Seagens website at...
Seagen Inc. (Nasdaq: SGEN) today announced results from two parts of a phase 2 trial (SGN35-027) evaluating ADCETRIS (brentuximab vedotin) in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine (AN+AD) for the frontline treatment of patients...
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope PR Newswire PALM BEACH, Fla., Dec. 1, 2022 FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Dec. 1, 2022 /PRNewswire/ -- The...